Shenzhen, China - The duck genome consortium, consisted of scientists from China Agricultural University, BGI, University of Edinburgh and other institutes has completed the genome sequencing and analysis of the duck (Anas platyrhynchos), one principal natural host of influenza A viruses. This work reveals some noteworthy conclusions and provides an invaluable resource for unraveling the interactive mechanisms between the host and influenza viruses.
The new H7N9 bird flu strain killed 36 people and caused $6.5 billion loss to China's economy. As a natural host of influenza A viruses (including H5N1), the duck is known to often remain asymptomatic under influenza infection. To uncover the interactive mechanisms between the host and influenza viruses, researchers sequenced the genome of a 10-week-old female Beijing duck, and conducted transcriptomic studies on two virus-infected ducks.
This work yielded the draft sequence of a waterfowl-duck for the first time, and the data indicated that the duck, like the chicken and zebra finch, possessed a contractive immune gene repertoire comparing to those in mammals, and it also comprises novel genes that are not present in the other three birds (chicken, zebra finch and turkey).
By comparing gene expression in the lungs of ducks infected with either highly or weakly pathogenic avian influenza H5N1 viruses, the team identified genes whose expression patterns were altered in response to avian influenza viruses. They also identify factors that may be involved in duck host immune response to avian virus infection, including the avian and mammalian -defensin gene families.
Jianwen Li, project manager from BGI, said, "This study provides very important data to better understand the interaction between the host and the avian influenza. Scientists will be able to explore more deeply the mechanisms on the spread and infection of avian influenza."
BGI was founded in Beijing, China, in 1999 with the mission to become a premier scientific partner for the global research community. The goal of BGI is to make leading-edge genomic science highly accessible, which it achieves through its investment in infrastructure, leveraging the best available technology, economies of scale, and expert bioinformatics resources. BGI, and its affiliates, BGI Americas, headquartered in Cambridge, MA, and BGI Europe, headquartered in Copenhagen, Denmark, have established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, supporting a variety of disease, agricultural, environmental, and related applications.
BGI has a proven track record of excellence, delivering results with high efficiency and accuracy for innovative, high-profile research: research that has generated over 200 publications in top-tier journals such as Nature and Science. BGI's many accomplishments include: sequencing one percent of the human genome for the International Human Genome Project, contributing 10 percent to the International Human HapMap Project, carrying out research to combat SARS and German deadly E. coli, playing a key role in the Sino-British Chicken Genome Project, and completing the sequence of the rice genome, the silkworm genome, the first Asian diploid genome, the potato genome, and, more recently, have sequenced the human Gut Metagenome, and a significant proportion of the genomes for the 1000 Genomes Project.
For more information about BGI, please visit http://www.
Public Communications Officer